Noble Life Science Partners
    Nathan Cali

    Communiqués de Presse

     

    Veuillez noter : La langue de travail principale de Aequus Pharmaceuticals Inc., est l'anglais. Les investisseurs sont invités à visiter le site Web anglais pour lire les communiqués de presse en cliquant ici.

    Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio

    Aequus Expands Market in Quebec for Tacrolimus IR

    FDA Confirms Date to Providing Regulatory Guidance for Aequus’ Anti-Nausea Patch

    Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch

    Aequus Announces Change to Proposed $300,000 Equity Financing

    Aequus Announces Proposed $300,000 Equity Financing

    Aequus announces the issuance of stock options

    Aequus Provides Third Quarter 2017 Operational Highlights

    Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

    Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

    Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

    Aequus Provides Second Quarter 2017 Operational Highlights

    Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole

    Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000

    Aequus Receives Approval from Health Canada to Initiate Proof of Concept Clinical Trial of Anti-Nausea Patch

    Aequus Advances Clinical Development of Transdermal Anti-Nausea Patch